-

VisionQuest Biomedical Inc. to Participate in Virtual Exhibit at the World Ophthalmology Congress 2020

ALBUQUERQUE, N.M.--(BUSINESS WIRE)--VisionQuest Biomedical Inc. announces that the company will be participating as an exhibitor in the World Ophthalmology Congress virtual meeting (WOC2020 Virtual) to take place June 26–29, 2020.

The 37th World Ophthalmology Congress will be an online experience that showcases the latest developments in all fields of ophthalmology. It will be attended by representatives from 182 national, regional, and subspecialty member societies from all over the world. The virtual exhibition will be open during the days of the meeting and for three months after its conclusion. VisionQuest joins a select group of leading ophthalmic companies in presenting our artificial intelligence (AI) solutions to end preventable blindness.

VisionQuest is presenting its flagship AI technologies: EyeStar and ASPIRE. EyeStar detects diabetic retinopathy, the most common complication of diabetes for the more than 630 million people with the disease worldwide and the leading cause of blindness in the working-age population. EyeStar has been deployed in fifteen clinics in Mexico and has screened over 28,000 people with diabetes for eye disease. ASPIRE uses a smartphone imaging device and AI software to detect malarial retinopathy, a highly specific sign of cerebral malaria, which kills over 100,000 African children every year. ASPIRE is currently being tested in Malawi, Kenya, and Zambia.

VisionQuest seeks to expand its products’ footprint worldwide, and the WOC2020 provides an excellent platform from which to interact with ophthalmologists internationally. Dr. Simon Barriga (PhD), CEO of VisionQuest, says, “In this time when most in-person conferences have been cancelled, the WOC2020 Virtual exhibit provides us with a great opportunity to connect with ophthalmologists from all over the world and create meaningful relationships to expand the reach of our technologies.”

VisionQuest’s participation is made possible by funding from the New Mexico Economic Development Department’s Office of Science & Technology, which focuses on growing and diversifying existing New Mexico-based technology companies, rapidly commercializing new technologies, and promoting research and development in emerging technologies.

About VisionQuest Biomedical Inc.: VisionQuest develops and delivers innovative artificial intelligence–based imaging technologies that increase access to health care for the people who need it the most. We aim to serve patients and providers in the most humane, efficient, and cost-effective ways possible.

Contacts

Simon Barriga
VisionQuest Biomedical Inc.
505-508-1994
sbarriga@visionquest-bio.com

Industry:

VisionQuest Biomedical Inc.


Release Versions

Contacts

Simon Barriga
VisionQuest Biomedical Inc.
505-508-1994
sbarriga@visionquest-bio.com

Social Media Profiles
More News From VisionQuest Biomedical Inc.

VisionQuest Uses Artificial Intelligence to Screen 40,000 Patients for Diabetic Retinopathy

ALBUQUERQUE, New Mexico--(BUSINESS WIRE)--VisionQuest Biomedical Inc. announces that the company has used the EyeStar artificial intelligence (AI) software to screen over 40,000 patients for diabetic retinopathy at the Clínicas del Azúcar. The EyeStar AI system screens patients for diabetic retinopathy and macular edema, conditions that lead to vision loss and blindness if left untreated. VisionQuest brought the EyeStar AI system to Clínicas del Azúcar in 2016, and since then the software has i...

VisionQuest Receives a $2M NIH Grant to Commercialize an Artificial Intelligence System Used to Improve and Save the Lives of African Children Affected with Malaria

ALBUQUERQUE, N.M.--(BUSINESS WIRE)--VisionQuest Biomedical Inc. announces that it has been awarded a $2M grant from the National Institutes of Health’s National Institute of Allergy and Infectious Diseases to commercialize ASPIRE, a device that uses artificial intelligence (AI) to improve the diagnosis of cerebral malaria. Every year, up to 100,000 children in Africa die from cerebral malaria. Up to a third of fatal cases could be prevented by a more accurate diagnosis of the disease. ASPIRE in...

VisionQuest Biomedical Inc. Gains FDA 510(k) Clearance for the Image Quality Analyzer Software

ALBUQUERQUE, N.M.--(BUSINESS WIRE)--VisionQuest Biomedical Inc. (VisionQuest) announced today that the company has received 510(k) clearance from the United States Food and Drug Administration (FDA) to market the Image Quality Analyzer (IQA) software, which reduces unreadable images captured in teleretinal screening programs by retinal photographers. The IQA is a software system intended for use in importing, displaying, analyzing and managing images acquired with digital fundus cameras. The pa...
Back to Newsroom